Johnson & Johnson bets heavy on AI-driven drug discovery

Off Biotech, biotechnology, Business, drug development, drug pricing, FDA, genetics, government agencies, Health, health care, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about how ADCs are having a heyday, and ponder the zombie microcap.

Read the rest…

Read Original Article: Johnson & Johnson bets heavy on AI-driven drug discovery »

About The Author